December 20, 2016

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2006-005893-37/ Novartis Protocol ID CZOL446M2307

A one year multicenter, randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety of a single intravenous 5 mg dose zoledronic acid for the treatment of osteoporosis in men

Trial CZOL446M2307 was cancelled with no patient enrollment and as such, no results will be reported.